Drug intelligence / Profile preview

T-62

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

T-62 is a small molecule drug initially developed by King Pharmaceuticals LLC and later associated with Pfizer Inc. It acts as an adenosine receptor agonist, specifically functioning as an adenosine A1 allosteric enhancer. This mechanism increases the effectiveness of the body's endogenous adenosine to treat neuropathic pain. The drug was investigated primarily for the treatment of postherpetic neuralgia, a type of chronic pain following shingles infection. Clinical development included Phase 2 trials; however, its development status is discontinued.

Targets

ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on T-62.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-62.

Explore the full profile